US Patent 7998973 Tivozanib and temsirolimus in combination
Patent 7998973 was granted and assigned to AVEO Pharmaceuticals on August, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+486 characters)
Article
Patent abstract
A method of treating a tumor in a human patient is disclosed. The method comprises co-administering to the patient: (a) a dose of 1.5 mg tivozanib per day; and (b) a dose of 25 mg temsirolimus per week. In some embodiments of the invention, the tivozanib is administered on a repeating schedule of one dose per day for three weeks, followed by one week without tivozanib administration. The disclosed method is particularly suitable for treatment of renal cell carcinoma.
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07998973 Tivozanib and temsirolimus in combination US Patent 7998973 Tivozanib and temsirolimus in combination
Infobox
Patent Number
0799897300
Patent Number
799897300
Edits on 22 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
079989730
Date of Patent
August 16, 2011
0Patent Application Number
128564140
Date Filed
August 13, 2010
0Patent Primary Examiner
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
079989730
Date of Patent
August 16, 2011
0Patent Application Number
128564140
Date Filed
August 13, 2010
0Patent Primary Examiner
Edits on 8 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07998973 Tivozanib and temsirolimus in combination
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07998973
Date of patent
August 16, 2011
Patent application number
12856414
Date Filed
August 13, 2010
Patent primary examiner
Find more entities like US Patent 7998973 Tivozanib and temsirolimus in combination
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
